BRKR Bruker (BRKR) Insider Trading, Ownership & Congress Trades
Medical Devices · Laboratory analytical instruments · CIK 0001109354
Form 144 · 3
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
249
13F, latest reported quarter
Conversions, 180 days
5
Codes C/M, not in net · $221.9K priced
What the filings say about BRKR
Insiders, 180 days
-$736.4K net sold
2 sellers · 0% of sales under a 10b5-1 plan
Planned sales (Form 144), 90 days
$418.6K
3 notices
Bruker insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
Over the last 180 days, BRUKER CORP insiders sold a net $736.4K of stock across 67 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-28.
Insider
Filed
Shares
Value
Since filing
Context
- 13 earlier Form 4 trades (code P or S) here by this insider (13 sales), the last on Aug 14, 2026.
- The trade is 1.5% of the 134,806 shares held after it.
- 1 other insider sold within 30 days.
- 249 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: EXEC VP&PRES BRUKER NANO INC. Munch Mark sold about $105.7K of BRKR on Sep 15, 2026; 1 other insider sold within 30 days and 249 funds added in the latest 13F quarter.Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 35.4% of the 9,801 shares held after it.
- 1 other insider sold within 30 days.
- 249 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: President BMID Group Pusch Wolfgang sold about $197.6K of BRKR on Aug 17, 2026; 1 other insider sold within 30 days and 249 funds added in the latest 13F quarter.Context
- 12 earlier Form 4 trades (code P or S) here by this insider (12 sales), the last on Jul 15, 2026.
- The trade is 1.6% of the 123,347 shares held after it.
- 1 other insider sold within 30 days.
- 249 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: EXEC VP&PRES BRUKER NANO INC. Munch Mark sold about $115.2K of BRKR on Aug 14, 2026; 1 other insider sold within 30 days and 249 funds added in the latest 13F quarter.Context
- 11 earlier Form 4 trades (code P or S) here by this insider (11 sales), the last on Jun 15, 2026.
- The trade is 1.6% of the 128,443 shares held after it.
- No other insider sold within 30 days.
- 249 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: EXEC VP&PRES BRUKER NANO INC. Munch Mark sold about $120.5K of BRKR on Jul 15, 2026; 249 funds added in the latest 13F quarter.Context
- 10 earlier Form 4 trades (code P or S) here by this insider (10 sales), the last on May 15, 2026.
- The trade is 1.6% of the 128,443 shares held after it.
- No other insider sold within 30 days.
- 249 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: EXEC VP&PRES BRUKER NANO INC. Munch Mark sold about $109.5K of BRKR on Jun 15, 2026; 249 funds added in the latest 13F quarter.67 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
net -$736.4K over 180 days
-$418.6K over 90 days
below 59% of Medical Devices
Congress
no House purchase disclosed in the last 12 months
Funds
249 funds bought in last quarter
more than 87% of Medical Devices
Revenue
+2.1% year over year
below 72% of Medical Devices
Margin
-0.3% net margin
more than 67% of Medical Devices
Buybacks
$10.0M repurchased, FY to 2025-12-31
below 61% of Medical Devices
Short interest
12.2% of the float short (float per yahoo 2026-10-27) · 5.7 days to cover · settled 2026-10-15
more than 82% of Medical Devices
What changed in the last 30 days
Nothing new filed in the last 30 days
Watch BRKR
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+53.5%12M
Insider sellForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns BRKR: institutional holders (13F)
13F holdings, latest reported quarter
20,683,975 sh
$1.4B
17,940,076 sh
$1.1B
11,579,027 sh
$763.4M
9,483,978 sh
$570.7M
4,888,290 sh
$294.2M
Congress trades in BRKR
No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
BRKR planned insider sales (Form 144)
Notice of intent to sell, filed before any sale
MARK R MUNCH
Filed 2026-09-15
$105.7K
WOLFGANG PUSCH
Filed 2026-08-17
$197.6K
MARK R MUNCH
Filed 2026-08-14
$115.2K
MARK R MUNCH
Filed 2026-07-15
$120.5K
BRKR mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
Global X SuperIncome Preferred ETF
$6.1M position · as of 2026-07-31
4.3%
First Trust NYSE Arca Biotechnology Index Fund
$121.5M position · as of 2026-06-30
4.3%
ALGER HEALTH SCIENCES FUND
$3.0M position · as of 2026-07-31
4.0%
Carillon Chartwell Mid Cap Value Fund
$591.0K position · as of 2026-06-30
3.1%
Franklin Small Cap Value VIP Fund
$35.1M position · as of 2026-06-30
2.7%
Touchstone Funds Group Trust-Touchstone Mid Cap Fund
$115.5M position · as of 2026-06-30
2.6%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Executive pay vs shareholder return · Frank HLaukien Ph D
CEO pay, headline and as actually paid, against the company's
return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2024
$5.5M
$3.2M
$2.1M
+10%
-30%
2023
$5.9M
$6.3M
$2.0M
+37%
-25%
2022
$5.1M
$1.9M
$1.7M
+27%
-16%
2021
$5.6M
$14.3M
$2.0M
+55%
+26%
Tagged by the company under SEC Item 402(v). Returns are
cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders have filed to sell, before selling.
The record shows a net $736.4K sold by insiders over 180 days, 249 funds added last quarter, $418.6K in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
BRKR financials
Revenue growth
+2.1%
XBRL, annual
Net margin
-0.3%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$3.5B
four quarters, 2025-07-01 to 2026-06-30
Revenue, TTM BRKR
| FY Dec 2025 | $3.4B |
| FY Dec 2024 | $3.4B |
| FY Dec 2023 | $3.0B |
| FY Dec 2022 | $2.5B |
| FY Dec 2021 | $2.4B |
| Jun 2026 | $838.5M |
| Mar 2026 | $823.4M |
| Dec 2025 | $977.2M |
| Sep 2025 | $860.5M |
| Jun 2025 | $797.4M |
| Mar 2025 | $801.4M |
| Dec 2024 | $979.6M |
| Sep 2024 | $864.4M |
At each fiscal year end
Single quarter
Net margin, TTM
-2.0%
net income over revenue, 2025-07-01 to 2026-06-30
Net margin, TTM BRKR
| FY Dec 2025 | -0.2% |
| FY Dec 2024 | +3.4% |
| FY Dec 2023 | +14.5% |
| FY Dec 2022 | +11.8% |
| FY Dec 2021 | +11.6% |
| Jun 2026 | -6.2% |
| Mar 2026 | +1.7% |
| Dec 2025 | +2.7% |
| Sep 2025 | -6.9% |
| Jun 2025 | +1.0% |
| Mar 2025 | +2.2% |
| Dec 2024 | +1.5% |
| Sep 2024 | +4.7% |
At each fiscal year end
Single quarter
Free cash flow, TTM
$93.9M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Free cash flow, TTM BRKR
| FY Dec 2025 | $43.3M |
| FY Dec 2024 | $136.0M |
| FY Dec 2023 | $243.2M |
| FY Dec 2022 | $145.2M |
| FY Dec 2021 | $190.4M |
| Jun 2026 | -$106.2M |
| Mar 2026 | $47.0M |
| Dec 2025 | $207.2M |
| Sep 2025 | -$54.1M |
| Jun 2025 | -$148.8M |
| Mar 2025 | $39.0M |
| Dec 2024 | $153.3M |
| Sep 2024 | $5.8M |
At each fiscal year end
Single quarter
Debt to equity
0.76x
long-term debt only, 2026-06-30; equity 2026-06-30
Debt to equity BRKR
| FY Dec 2025 | 0.75x |
| FY Dec 2024 | 1.16x |
| FY Dec 2023 | 0.84x |
| FY Dec 2022 | 1.08x |
| FY Dec 2021 | 1.14x |
| Jun 2026 | 0.76x |
| Mar 2026 | 0.67x |
| Dec 2025 | 0.75x |
| Sep 2025 | 0.82x |
| Jun 2025 | 1.31x |
| Mar 2025 | 1.13x |
| Dec 2024 | 1.16x |
| Sep 2024 | 1.25x |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
0.10x
TTM operating cash flow over long-term debt only, 2026-06-30
Cash flow to debt BRKR
| FY Dec 2025 | 0.07x |
| FY Dec 2024 | 0.12x |
| FY Dec 2023 | 0.30x |
| FY Dec 2022 | 0.23x |
| FY Dec 2021 | 0.23x |
| Jun 2026 | 0.10x |
| Mar 2026 | 0.08x |
| Dec 2025 | 0.07x |
| Sep 2025 | 0.05x |
| Jun 2025 | 0.07x |
| Mar 2025 | 0.14x |
| Dec 2024 | 0.12x |
| Sep 2024 | 0.12x |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
-3.4%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on equity BRKR
| FY Dec 2025 | -0.4% |
| FY Dec 2024 | +7.2% |
| FY Dec 2023 | +34.4% |
| FY Dec 2022 | +27.3% |
| FY Dec 2021 | +27.6% |
| Jun 2026 | -3.4% |
| Mar 2026 | -0.5% |
| Dec 2025 | -0.4% |
| Sep 2025 | -1.0% |
| Jun 2025 | +4.5% |
| Mar 2025 | +4.9% |
| Dec 2024 | +7.2% |
| Sep 2024 | +20.3% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
-1.1%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets BRKR
| FY Dec 2025 | -0.1% |
| FY Dec 2024 | +2.3% |
| FY Dec 2023 | +10.9% |
| FY Dec 2022 | +8.2% |
| FY Dec 2021 | +8.4% |
| Jun 2026 | -1.1% |
| Mar 2026 | -0.2% |
| Dec 2025 | -0.1% |
| Sep 2025 | -0.3% |
| Jun 2025 | +1.3% |
| Mar 2025 | +1.5% |
| Dec 2024 | +2.3% |
| Sep 2024 | +6.2% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
pre-tax loss, no effective tax rate to apply
Return on invested capital BRKR
| FY Dec 2025 | n/a |
| FY Dec 2024 | +4.3% |
| FY Dec 2023 | +18.6% |
| FY Dec 2022 | +21.7% |
| FY Dec 2021 | +21.6% |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | +2.5% |
| Mar 2025 | n/a |
| Dec 2024 | +4.3% |
| Sep 2024 | +6.3% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
-0.6%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
Return on capital employed BRKR
| FY Dec 2025 | +1.4% |
| FY Dec 2024 | +6.7% |
| FY Dec 2023 | +15.2% |
| FY Dec 2022 | +16.0% |
| FY Dec 2021 | +16.6% |
| Jun 2026 | -0.6% |
| Mar 2026 | +1.0% |
| Dec 2025 | +1.4% |
| Sep 2025 | +1.3% |
| Jun 2025 | +3.8% |
| Mar 2025 | +5.6% |
| Dec 2024 | +6.7% |
| Sep 2024 | +7.5% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
P/E, trailing BRKR
| FY Dec 2025 | n/a |
| FY Dec 2024 | 77.13x |
| FY Dec 2023 | 25.25x |
| FY Dec 2022 | 34.35x |
| FY Dec 2021 | 46.36x |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | 79.23x |
| Mar 2025 | 80.27x |
| Dec 2024 | 77.13x |
| Sep 2024 | 33.36x |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
$10.8B
market value at close 2026-10-27 on 2025-07-29 shares, plus long-term debt only, 2026-06-30, minus cash 2026-06-30
Enterprise value BRKR
| FY Dec 2025 | $8.7B |
| FY Dec 2024 | $10.8B |
| FY Dec 2023 | $10.8B |
| FY Dec 2022 | $10.6B |
| FY Dec 2021 | $12.9B |
| Jun 2026 | $10.8B |
| Mar 2026 | $7.0B |
| Dec 2025 | $8.7B |
| Sep 2025 | $6.6B |
| Jun 2025 | $8.5B |
| Mar 2025 | $8.2B |
| Dec 2024 | $10.8B |
| Sep 2024 | $12.6B |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
+1.0%
TTM free cash flow over market value at close 2026-10-27
FCF yield BRKR
| FY Dec 2025 | +0.6% |
| FY Dec 2024 | +1.5% |
| FY Dec 2023 | +2.4% |
| FY Dec 2022 | +1.4% |
| FY Dec 2021 | +1.5% |
| Jun 2026 | +1.0% |
| Mar 2026 | +0.9% |
| Dec 2025 | +0.6% |
| Sep 2025 | -0.2% |
| Jun 2025 | +0.8% |
| Mar 2025 | +2.8% |
| Dec 2024 | +1.5% |
| Sep 2024 | +1.5% |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
PEG, trailing BRKR
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | 0.55x |
| FY Dec 2022 | 3.45x |
| FY Dec 2021 | 0.61x |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-27. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Revenue | $3.4B | $3.4B | $3.0B | $2.5B |
| Gross profit | $1.6B | $1.6B | $1.5B | $1.3B |
| Operating income | $68.2M | $253.1M | $436.9M | $432.7M |
| Net income | -$8.3M | $113.8M | $428.5M | $298.5M |
| EPS (diluted) | -0.15 | 0.76 | 2.90 | 1.99 |
| Operating cash flow | $134.1M | $251.3M | $350.1M | $274.4M |
| Cash | $298.8M | $183.4M | $488.3M | $645.5M |
| Long-term debt | $1.9B | $2.1B | $1.2B | $1.2B |
| Buybacks | $10.0M | $0 | $152.3M | $263.1M |
| Dividends paid | $22.8M | $30.2M | $29.4M | $29.8M |
SEC XBRL, fiscal years, as known on 2026-10-28
BRKR Stock Sonar score 6/7 axes
Find similar shapesCompareBRKR ranks highest on institutional and government (87th percentile) and profitability (66th), and lowest on insider conviction (19th), among Medical Devices peers.
6 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
BRKR filings, in plain words
Are Bruker insiders buying or selling BRKR?
In the 180 days to 2026-10-28, Bruker insiders were net sellers, a net $736.4K across purchases and sales reported on Form 4, by 2 sellers.
Are there planned insider sales of BRKR?
Yes. 3 Form 144 notices of planned insider sales were filed in the 90 days to 2026-10-28, covering $418.6K of stock; the latest, by MARK R MUNCH, was filed 2026-09-15.
Read the full summary
In the 180 days to 2026-10-28, Bruker insiders were net sellers of BRKR, a net $736.4K across purchases and sales reported on Form 4 by 2 sellers. None of the 6 insider sales was flagged as made under a Rule 10b5-1 plan. Insiders filed 3 Form 144 notices of intent to sell in the 90 days to 2026-10-28, covering $418.6K of stock. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
